Enanta Pharmaceuticals Depreciation And Amortization Over Time
| ENTA Stock | USD 8.56 0.45 4.99% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Enanta Pharmaceuticals Performance and Enanta Pharmaceuticals Correlation. Enanta |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (5.45) | Revenue Per Share 3.407 | Quarterly Revenue Growth (0.05) | Return On Assets (0.17) |
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Depreciation And Amortization Analysis
Compare Enanta Pharmaceuticals and related stocks such as Monte Rosa Therapeutics, Design Therapeutics, and Werewolf Therapeutics Depreciation And Amortization Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GLUE | 348 K | 348 K | 348 K | 348 K | 348 K | 348 K | 348 K | 348 K | 348 K | 348 K | 537 K | 2.1 M | 8.6 M | 6.2 M | 3.9 M |
| DSGN | 1.9 K | 1.9 K | 1.9 K | 1.9 K | 1.9 K | 1.9 K | 1.9 K | 1.9 K | 1.9 K | 1.9 K | 5 K | 129 K | 406 K | 537 K | 563.9 K |
| HOWL | 463 K | 463 K | 463 K | 463 K | 463 K | 463 K | 463 K | 463 K | 463 K | 463 K | 777 K | 216 K | 1.1 M | 1.8 M | 951.3 K |
| IKNA | 243 K | 243 K | 243 K | 243 K | 243 K | 243 K | 243 K | 243 K | 243 K | 243 K | 1.3 M | 1.7 M | 2 M | 1 M | 1.4 M |
| STOK | 113 K | 113 K | 113 K | 113 K | 113 K | 113 K | 113 K | 113 K | 214 K | 450 K | 888 K | 974 K | 1.5 M | 2.5 M | 2.6 M |
| CRNX | 92 K | 92 K | 92 K | 92 K | 92 K | 92 K | 92 K | 128 K | 471 K | 887 K | 948 K | 922 K | 983 K | 1.1 M | 760.2 K |
| INBX | 399 K | 399 K | 399 K | 399 K | 399 K | 399 K | 399 K | 399 K | 676 K | 1.1 M | 1 M | 1.2 M | 1.2 M | 1.2 M | 1.1 M |
| MRUS | 364.6 K | 364.6 K | 364.6 K | 364.6 K | 307.7 K | 211 K | 246.1 K | 381.5 K | 729.8 K | (1.6 M) | 1.4 M | 1.5 M | 1.3 M | 2.5 M | 2.7 M |
| LYEL | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 7.5 M | 14.5 M | 16.5 M | 20.2 M | 13.9 M |
| KRON | 91 K | 91 K | 91 K | 91 K | 91 K | 91 K | 91 K | 91 K | 91 K | 356 K | 4.9 M | 236.6 K | 2.3 M | 2.1 M | 1.8 M |
| IPSC | 227.4 M | 227.4 M | 227.4 M | 227.4 M | 227.4 M | 227.4 M | 227.4 M | 227.4 M | 227.4 M | 227.4 M | 1.8 M | 4.6 M | 10.1 M | 13 M | 12.4 M |
| EWTX | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 185 K | 272 K | 538 K | 1.6 M | 1.6 M |
| CCCC | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.6 M | 2.8 M | 2.9 M | 7.6 M | 7.7 M | 4.4 M |
| MLYS | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 18.7 M | 228.5 K | 167.9 K | 159.5 K |
| CGEM | 43 K | 43 K | 43 K | 43 K | 43 K | 43 K | 43 K | 43 K | 43 K | 70 K | 62 K | 53 K | 93 K | 310 K | 325.5 K |
| RVMD | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.8 M | 5.5 M | 6.5 M | 7.3 M | 9.7 M | 9.3 M | 6.5 M |
Enanta Pharmaceuticals and related stocks such as Monte Rosa Therapeutics, Design Therapeutics, and Werewolf Therapeutics Depreciation And Amortization description
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.My Equities
My Current Equities and Potential Positions
| Enanta Pharmaceuticals | ENTA |
| Classification | Trump Equities |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 8.56
Check out Enanta Pharmaceuticals Performance and Enanta Pharmaceuticals Correlation. For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Enanta Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.